Site search

Clear filter
2880 results for '' found
A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies (BGB-11417-101) (NCT04277637)
A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies (BGB-11417-101) (NCT04277637)
/
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients w
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients w
/
Bevacizumab and immune chEckpoint inhibitors plus hypofractionated stereotactic radioTherapy for the treatment of sympTomatic mElanoma bRain metastases (NCT06163820)
Bevacizumab and immune chEckpoint inhibitors plus hypofractionated stereotactic radioTherapy for the treatment of sympTomatic mElanoma bRain metastases (NCT06163820)
/
AN OPEN-LABEL, NON-INVESTIGATIONAL PRODUCT, LEAD-IN STUDY TO EVALUATE AT LEAST 6 MONTHS OF PROSPECTIVE EFFICACY AND SAFETY DATA OF FACTOR IX OR FACTOR VIII PROPHYLAXIS REPLACEMENT THERAPY IN THE
AN OPEN-LABEL, NON-INVESTIGATIONAL PRODUCT, LEAD-IN STUDY TO EVALUATE AT LEAST 6 MONTHS OF PROSPECTIVE EFFICACY AND SAFETY DATA OF FACTOR IX OR FACTOR VIII PROPHYLAXIS REPLACEMENT THERAPY IN THE
/
A phase I/II single arm study of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma. (ACTRN12620000490976)
A phase I/II single arm study of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma. (ACTRN12620000490976)
/
A randomised, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (NCT06097260)
/
Adding mitomycin C to BCG as adjuvant intravesical therapy for high risk, non–muscle invasive bladder cancer: A randomised phase 3 trial (ACTRN12613000513718)
Adding mitomycin C to BCG as adjuvant intravesical therapy for high risk, non–muscle invasive bladder cancer: A randomised phase 3 trial (ACTRN12613000513718)
/
Bazedoxifene – A New Selective Estrogen Receptor Modulator Treatment for Women with Schizophrenia: a double-blind, randomized, placebo controlled trial (NCT04113993)
Bazedoxifene – A New Selective Estrogen Receptor Modulator Treatment for Women with Schizophrenia: a double-blind, randomized, placebo controlled trial (NCT04113993)
/
Bazedoxifene – A New Selective Estrogen Receptor Modulator Treatment for Men with Schizophrenia: a double-blind, randomized, placebo-controlled trial (ACTRN12619001471178p)
Bazedoxifene – A New Selective Estrogen Receptor Modulator Treatment for Men with Schizophrenia: a double-blind, randomized, placebo-controlled trial (ACTRN12619001471178p)
/
A PHASE Ib/II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, ACTIVITY, AND PHARMACOKINETICS OF GDC-6036 IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH PREVIOUSLY UNTREATE
A PHASE Ib/II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, ACTIVITY, AND PHARMACOKINETICS OF GDC-6036 IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH PREVIOUSLY UNTREATE
/
58 59 60 61 62